Vedolizumab Maintenance Therapy for Ulcerative Colitis

Medical Necessity: Strongly Supported by Guidelines

• The British Society of Gastroenterology recommends vedolizumab for maintenance of remission in patients with moderate to severe ulcerative colitis (conditional recommendation, moderate certainty evidence) 1
• The Toronto Consensus Guidelines provide a strong recommendation for continued vedolizumab therapy to maintain corticosteroid-free remission in patients who respond to induction therapy (strong recommendation, moderate-quality evidence) 2

Safety Profile: Well-Established and Favorable

• The proportion of patients experiencing adverse events is similar between vedolizumab and placebo groups (84% vs 87%), as is the rate of serious adverse events (12% vs 14%) 2

Duration of Therapy: Guideline-Supported Long-Term Use

• Guidelines explicitly recommend ongoing maintenance therapy in patients who respond to induction with vedolizumab, with treatment continuing as long as clinical benefit is maintained 2
• The British Society of Gastroenterology notes that treatment effect may be smaller in patients with prior anti-TNF therapy exposure, but this does not negate medical necessity—it simply requires appropriate patient selection and monitoring 1